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Background: The pathogenesis of inflammatory bowel disease (IBD) involves interactions between the host
genetic susceptibility, intestinal microflora and mucosal immune responses through the pattern recognition
receptor. Polymorphisms in toll-like receptor 4 (TLR4) induce an aberrant immune response to indigenous intestinal
flora, which might favor IBD development. In this study, we aimed to determine whether TLR4 gene was associated
with Crohn ? s disease (CD) and ulcerative colitis (UC) among Moroccan patients, and evaluated its correlation with
clinical manifestation of the disease.
Methods: The study population comprised 117 patients with IBD and 112 healthy unrelated blood donors. TLR4
polymorphisms: Asp299Gly and Thr399Ile were genotyped by polymerase chain reaction-restriction fragment length
polymorphism. PCR products were cleaved with Nco I for the Asp299Gly polymorphism and Hinf I for the Thr399Ile
polymorphism. Meta-analysis was performed to test the association of 299Gly and 399Ileu carriage with CD, UC and
the overall IBD risk.
Results: Our study revealed that the frequency of Asp299Gly and Thr399Ile did not differ significantly between
patients and controls in the Moroccan population. However, meta-analysis demonstrated significantly higher
frequencies of both Asp299Gly and Thr399Ile SNPs in IBD and CD and for 399Ileu carriage in UC patients.
Conclusion: The meta-analysis provides evidence that TLR4 polymorphisms confer a significant increased risk for the
overall IBD development.
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Inflammatory bowel disease (IBD) is an idiopathic and
chronic multifactorial disease of the gastrointestinal tract.
Although the precise etiology of IBD is unclear, several
factors that play a crucial role in disease pathogenesis such
as commensal bacterial flora and genes related to the host
immune response have been identified [1,2].
Toll-like receptors are pattern recognition receptors
through which host recognizes microbial conserved mo-
lecular motifs that are broadly shared by pathogens, there-
fore they are very important for the regulation of mucosal
innate immune responses to intestinal microbes. Perturba-
tions in individual TLR biological signaling can prime to a* Correspondence: nezha.senhaji@gmail.com
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unless otherwise stated.number of different outcomes and elucidate a system of
regulation within the intestine in which each TLR plays a
largely non-redundant role in mucosal immunity.
TLR4 gene, the first mammalian TLR identified is
located on the long arm of human chromosome 9q32-33
[3]. It encodes the transmembrane receptor that initiates
the innate immune response to common gram-negative
bacteria [4,5].
TLR4 is the major transducer of lipopolysaccharide (LPS)
and binds specifically lipid A moiety. Signal transduction
through TLR4 in combination with CD14, and MD-2 leads
to activation of the nuclear factor-κB (NF-κB) system
through the MyD88-dependent and MyD88-independent
pathways and subsequent expression of inflammatory
genes encoding cytokines and cell conjugation molecules
as part of host defense mechanisms [6-9].
Under healthy conditions TLR4 is only minimally
expressed in lamina propria mononuclear cells (LPMNCs)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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LPS, thus preventing an exaggerated immune response
mediated by the large number of bacteria in the intestinal
lumen and maintaining a basal state of activation [10,11].
However, TLR4 expression is upregulated in hu-
man IBD colitis, maximizing responsiveness to the
environment and reflecting an aberrant state of acti-
vation [12-15]. Higher levels of TLR4 mRNA and
protein were found in the inflamed colonic mucosa
in pediatric IBD patients [16]. Two common co-
segregating polymorphisms affecting the extracellular
domain of the TLR4 (Asp299Gly and Thr399Ile)
have been described in humans. Individuals hetero-
zygous for these mutations have a blunted response
to inhaled LPS [17]. These polymorphisms are thought
to be associated with increased susceptibility to IBD. How-
ever, population studies reveal discordant results in geo-
graphical distribution.Table 1 Pooled analysis of studies exploring the role of TLR4
Study Cases (Events/Total) Contr
Arnott et al. 2004 [31] 50/468 33/37
Franchimont et al. 2004 [32] (1) 73/668 14/27
Franchimont et al. 2004 [32] (2) 26/226 14/27
Torok et al. 2004 [33] 14/204 12/29
Braat et al. 2005 [34] 68/822 13/27
Brand et al. 2005 [22] 29/408 15/39
Lakatos et al. 2005 [35] 104/1054 48/40
Gazouli et al. 2005 [36] 19/240 6/200
Oostenbrug et al. 2005 [37] 53/786 27/59
Ouburg et al. 2005 [38] 23/224 18/34
Fries et al. 2005 [39] (1) 2/46 2/118
Fries et al. 2005 [39] (2) 10/120 2/118
Zouiten-Mekki et al. 2009 [40] 12/180 9/160
Hong et al. 2007 [41] 26/364 32/37
Baumgart et al. 2007 [21] (1) 6/288 16/40
Baumgart et al. 2007 [21] (2) 28/482 49/80
Browning et al. 2007 [42] 50/778 44/83
De Ridder et al. 2007 [23] (1) 11/144 20/48
De Ridder et al. 2007 [23] (2) 63/756 20/48
Riis et al. 2007 [43] 32/422 152/1
Hume et al. 2008 [44] 87/1238 36/72
Rigoli et al. 2008 [45] 10/266 8/206
Manolakis et al. 2013 [46] 20/326 33/54
Current study 2014 9/166 10/22
Total (fixed effects) 825/10676 633/1
Total (random effects) 825/10676 633/1Thereby, we sought to investigate whether Asp299Gly
and Thr399Ile single nucleotide polymorphisms of the
gene encoding the TLR4 determine susceptibility to IBD
in Moroccan patients and assessed their influence on
phenotype expression.Methods
Study population
Enrolled in this study were 117 IBD Moroccan patients
(83 CD; 34 UC) and 112 healthy unrelated blood donors.
The diagnosis of CD or UC was established according to
conventional clinical, endoscopic, radiological and histo-
logical criteria as previously reported [18,19]. CD was
classified according to the Montreal classification [20].
The case report form included questions on disease
phenotype and location, age at diagnosis, toxic behavior
and other clinical features. The ethics committee of theAsp299Gly in CD
ols (Events/Total) Odds ratio 95% CI P value
8 1,25 0,79 to 1,98
8 2,31 1,28 to 4,17
8 2,45 1,25 to 4,81
0 1,70 0,77 to 3,77
4 1,81 0,98 to 3,33
8 1,95 1,03 to 3,70
0 0,80 0,56 to 1,15
2,78 1,09 to 7,10
2 1,51 0,94 to 2,43
0 2,04 1,08 to 3,88
2,63 0,36 to 19,29
5,27 1,13 to 24,60
1,19 0,49 to 2,92
6 0,82 0,48 to 1,42
4 0,51 0,20 to 1,33
6 0,95 0,59 to 1,54
2 1,23 0,81 to 1,86
8 1,93 0,91 to 4,14
8 2,12 1,27 to 3,56
236 0,58 0,39 to 0,87
0 1,43 0,96 to 2,14
0,96 0,38 to 2,49
8 1,02 0,58 to 1,81
4 1,22 0,49 to 3,09
0152 1,26 1,13 to 1,42 0.0001
0152 1,35 1,12 to 1,64
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proved the study and a written informed consent was
obtained from all human subjects.
Molecular analysis of TLR4 polymorphisms
Genomic DNA was extracted from peripheral blood
leukocytes using the salting out procedure. Two single
nucleotide variations, corresponding to two amino acid
polymorphisms for TLR4, were analyzed: the Asp299Gly
(896A/G), rs4986790 and the Thr399Ile (1196C/T),
rs4986791.
Typing of the polymorphisms was performed using poly-
merase chain reaction (PCR) restriction fragment length
polymorphism analysis (RFLP).
Upstream and downstream primers used for the PCR
amplification were:
F: (5′- AGCATACTTAGACTACTACCTCCATG-3′),






Reactions were performed in a 25 μl volume containing
200 μM of each dNTP (0.5 μl of dNTP mix, 10 mM each),
0.2 μM of each of the forward and reverse primers (0.5 μl
of each 10 μM primers), 2 mM MgCl2 (1 μl of MgCl2,Table 2 Pooled analysis of studies exploring the role of TLR4
Study Cases (Events/Total) Contr
Arnott et al. 2004 [31] 35/492 33/37
Franchimont et al. (1) 2004 [32] 32/326 14/27
Torok et al. 2004 [33] 18/196 12/29
Braat et al. 2005 [34] 24/452 13/27
Gazouli et al. 2005 [36] 6/170 6/200
Oostenbrug et al. 2005 [37] 21/358 27/59
Baumgart et al. 2007 [21] (1) 8/236 16/40
Baumgart et al. 2007 [21] (2) 24/290 49/80
Browning et al. 2007 [42] 51/810 44/83
Riis et al. 2007 [43] 53/808 152/1
De Ridder et al. 2007 [23] (1) 33/452 20/48
De Ridder et al. 2007 [23] (2) 4/62 20/48
Rigoli et al. 2008 [45] 3/90 8/206
Manolakis et al. 2013 [46] 41/374 33/54
Current study 2014 6/68 10/22
Total (fixed effects) 359/5184 457/7
Total (random effects) 359/5184 457/750 mM) and 1 U of Taq DNA polymerase (1 μl of 1U/μl
enzyme), 1? PCR buffer (2.5 μl of 10? PCR buffer).
PCR conditions comprised 5 min at 95?C then 35 cy-
cles of denaturing were performed at 95?C for 30 s, an-
nealing at 55?C (Asp299Gly) and at 53?C (Thr399Ile) for
1 min, 72?C for 30 s. A final extension phase of 72?C for
10 minutes was used.
PCR products were cleaved overnight at 37?C with Nco I
for Asp299Gly polymorphism and HinfI for Thr399Ile poly-
morphism (Biolabs). The digests were run on a 3% agarose
gel and visualized under UV light using ethidium bromide.
The mutant alleles (GG)/(TT) contained an Nco I/
Hinf I restriction site for the Asp299Gly/Thr399Ile poly-
morphisms respectively, allowing RFLP analysis of the
digested products. Digestion at the Nco I site yields frag-
ments of 168 and 20 bp, the one at Hinf I site yields
fragments of 98 and 26 bp. The wild-type allele for both
polymorphisms remained uncut.Statistical analysis
The data were analyzed with MedCalc 11.6. Chi-square test
was used to compare the allele and genotype frequencies
between disease and control groups. The Fisher ? s exact test
was used when appropriate. The observed genotype fre-
quencies were compared with the predicted frequencies by
the Hardy? Weinberg equilibrium.
The average age was determined by the rank sum test.
Associations between genotypes and risk of IBD wereAsp299Gly in UC
ols (Events/Total) Odds ratio 95% CI P value
8 0,801 0,49 to 1,31
8 2,052 1,07 to 3,93
0 2,343 1,10 to 4,98
4 1,126 0,56 to 2,25
1,183 0,37 to 3,73
2 1,304 0,72 to 2,34
4 0,851 0,36 to 2,02
6 1,394 0,84 to 2,31
2 1,203 0,79 to 1,82
236 0,501 0,36 to 0,69
8 1,843 1,04 to 3,26
8 1,614 0,53 to 4,88
0,853 0,22 to 3,29
8 1,921 1,19 to 3,10
4 2,071 0,72 to 5,92
244 1,092 0,94 to 1,26 0.20
244 1,268 0,95 to 1,69
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interval of 95% (CI). P values less than 0.05 were consid-
ered significant in disease risk association tests. The χ2
test or Fisher test was used to correlate the TLR4 poly-
morphisms and clinical parameters. The Bonferroni cor-
rection method was applied for correction for multiple
testing in sub-phenotype analysis; The phenotype geno-
type correlation was considered statistically significant if
the p value was less than 0.005 for CD and 0.007 for UC.
According to Power Calculator for Genetic Studies 2006
software (http://www.sph.umich.edu/csg/abecasis/CaTS/), this
study had 15% of power to detect an OR of 1.5.
TLR4 meta-analysis
Inclusion and exclusion criteria
Genetic association studies were included in our meta-
analysis if they met the following criteria:
(a) Studies that evaluated the association between the
TLR4 Asp299Gly, Thr399Ile polymorphisms and IBD,Table 3 Pooled analysis of studies exploring the role of TLR4
Study Sample size Cases (Events/Total)
Torok et al. 2004 [33] CD: 102 16/204
HC: 145
Braat et al. 2005 [34] CD: 204 30/408
HC: 199
Gazouli et al. 2005 [36] CD: 120 1/240
HC: 100
Oostenbrug et al. 2005 [37] CD: 393 69/1008
HC: 296
Zouiten-Mekki et al. 2009 [40] CD: 90 13/180
HC: 80
Hong et al. 2007 [41] CD: 182 30/364
HC: 188
Browning et al. 2007 [42] CD: 389 47/778
HC: 416
De Ridder et al. 2007 [23] CD: 450 72/900
HC: 244
Rigoli et al. 2008 [45] CD: 133 8/266
HC:103
Azzam et al. 2012 [47] CD: 46 26/92
HC: 50
Manolakis et al. 2013 [46] CD: 163 20/326
HC: 274
Our study 2014 CD: 83 7/166
HC: 112
Total (fixed effects) 339/4932
Total (random effects) 339/4932(b) A case ? control study design, (c) The study reported
sufficient data to calculate allele frequencies, odds ratios
and confidence intervals of cases and controls for car-
riage of the TLR4 299Gly and 399Ile alleles.
While major exclusion criteria were: (a) case-only
study and review articles (b) absence of the mutant
allele in both cases and controls, (c) studies without
the raw data of the TLR4 Asp299Gly and Thr399Ile
genotypes.
Pooled studies for case ? control meta-analysis
Twenty-four case? control studies were identified through
the literature search.
Asp299Gly polymorphism: According to the inclusion
criteria, twenty studies were retrieved in CD meta-
analysis (Table 1), four of them contained more than
one cohort [21-24]. UC meta-analysis reported data
from 13 of the included studies (Table 2); two of themThr399Ile in CD
Controls (Events/Total) Odds ratio 95% CI P value
12/290 1.972 0.91 to 4.26
19/398 1.583 0.87 to 2.86
2/200 0.414 0.037 to 4.60
29/598 1.442 0.92 to 2.25
8/160 1.479 0.59 to 3.66
32/376 0.966 0.57 to 1.62
46/832 1.099 0.72 to 1.67
22/488 1.842 1.12 to 3.00
6/206 1.034 0.35 to 3.02
22/100 1.397 0.72 to 2.69
33/548 1.020 0.57 to 1.80
3/224 3.243 0.82 to 12.73
234/4420 1.345 1.12 to 1.60 0.002
234/4420 1.336 1.11 to 1.59
Table 4 Pooled analysis of studies exploring the role of TLR4 Thr399Ile in UC
Study Sample size Cases (Events/Total) Controls (Events/Total) Odds 95% CI P value
Torok et al. 2004 [33] UC: 98 22/196 12/290 2.929 1.41 to 6.06
HC: 145
Gazouli et al. 2005 [36] UC: 85 3/170 2/200 1.778 0.29 to 10.77
HC: 100
Oostenbrug et al. 2005 [37] UC: 179 24/434 19/598 1.784 0.96 to 3.30
HC: 296
Zouiten-Mekki et al. 2009 [40] UC: 30 2/60 2/160 2.724 0.37 to 19.78
HC: 80
Browning et al. 2007 [42] UC: 405 59/810 46/832 1.342 0.90 to 1.99
HC: 416
De Ridder et al. 2007 [23] UC: 257 34/514 22/488 1.500 0.86 to 2.60
HC: 244
Rigoli et al. 2008 [45] UC: 45 3/90 6/206 1.149 0.28 to 4.70
HC:103
Manolakis et al. 2013 [46] UC: 187 41/374 33/548 1.921 1.19 to 3.10
HC: 274
Our study 2014 UC: 34 3/68 3/224 3.400 0.67 to 17.25
HC: 112
Total (fixed effects) 191/2716 145/3546 1.695 1.35 to 2.11 0.0001
Total (random effects) 191/2716 145/3546 1.699 1.35 to 2.12
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met one of the exclusion criteria [25-30].
Thr399Ile Polymorphism: twelve studies comprising
2466 cases and 2210 controls were included in CD
meta-analysis (Table 3), and nine of them in UC meta-
analysis with 1358 cases and 1773 controls (Table 4).
A meta-analysis combining CD and UC patients for the
two tested SNPs: Asp299Gly and Thr399Ile included 13
and 9 studies respectively (Tables 5 and 6).
The risk of IBD associated with the TLR4
polymorphism was estimated for each study by odds
ratio (OR) and 95% confidence interval (95% CI).
The meta-ORs were estimated using a fixed-effects
model with the wild-type allele as reference group.
Genetic heterogeneity was tested by Cochran ? s (Q) test,
I2 statistics was used to quantify the between-study
heterogeneity effect. When a significant Q test
(Q > 0.10; I2 > 50%) indicated heterogeneity across
studies, data were recombined using a random-effects
model to estimate common ORs. The meta-analyses
were conducted by Review Manager 5.0 and MedCalc
bvba 12.3.0 softwares.
Results
Hundred and seventeen patients with IBD (83 CD; 34
UC) and 112 control subjects from the general populationwere genotyped for the presence of TLR4Asp299Gly and
Thr399Ile polymorphisms.
The average age of CD, UC patients and controls was
27.6 ? 2.3, 40 ? 5.0 and 31.3 ? 2.1 years respectively. The
distributions of genotype and allele frequencies of both
TLR4Asp299Gly and Thr399Ile polymorphisms in CD
patients (X2 = 0.03, P = 0.86; X2 = 0.02, P = 0.90) and
healthy controls (X2 = 2.86, P = 0.24; X2 = 0.01, P = 0.94)
were in Hardy-Weinberg equilibrium. In patients with
UC, genotype and allele frequencies distributions for
Asp299Gly polymorphism (X2 = 0.03, P = 0.86) were in
Hardy-Weinberg equilibrium but not for Th399ILeu
polymorphism (X2 = 19.05, P <0.001).
In order to study associations of TLR4 variants in
IBD overall and in CD and UC in particular, the dis-
tribution of TLR4 polymorphic alleles was assessed.
Genotype and allele frequencies are given in Table 7
and genotypic and allelic odds ratios and test P-values
are presented in Table 8. None CD nor UC colitis
patients were homozygous for G allele. Mutant allele
frequency was 5.4% in CD, 8.8% in UC and 4.5% in HC.
No significant difference was noticed in allele distribu-
tions of the Asp299Gly polymorphism between the
control and patient groups. Likewise, no significant as-
sociation of IBD with the Thr399Ile polymorphism was
found in either cohort (allele frequencies: HC 1.3%, CD
Table 5 Pooled analysis of studies exploring the role of TLR4 Asp299Gly in IBD
Study Sample size Cases (Events/Total) Controls (Events/Total) Odds ratio 95% CI P value
Arnott et al. 2004 [31] IBD: 480 85/960 33/378 1,016 0,667 to 1,54
HC: 189
Franchimont et al. 2004 [32] IBD: 610 131/1220 14/278 2,268 1,286 to 4,00
HC: 139
Torok et al. 2004 [33] IBD: 200 32/400 12/290 2,014 1,019 to 3,98
HC: 145
Braat et al. 2005 [34] IBD: 637 92/1274 13/274 1,563 0,861 to 2,83
HC: 137
Gazouli et al. 2005 [36] IBD: 205 25/410 6/200 2,100 0,847 to 5,20
HC: 100
Oostenbrug et al. 2005 [37] IBD: 572 74/1144 27/592 1,447 0,921 to 2,27
HC: 296
Baumgart et al. 2007 [21] (1) IBD: 262 14/524 16/404 0,666 0,321 to 1,38
HC: 202
Baumgart et al. 2007 [21] (2) IBD: 386 52/772 49/806 1,116 0,745 to 1,67
HC: 403
Browning et al. 2007 [42] IBD: 796 101/1592 44/832 1,213 0,843 to 1,74
HC: 416
Riis et al. 2007 [43] IBD: 615 85/1230 152/1236 0,529 0,401 to 0,69
HC: 618
De Ridder et al. 2007 [23] IBD: 103 15/206 20/488 1,838 0,921 to 3,66
De Ridder et al. 2007 [23] IBD: 604 96/1208 20/488 2,020 1,233 to 3,31
HC: 244
Rigoli et al. 2008 [45] IBD: 178 13/356 8/206 0,938 0,382 to 2,30
HC: 103
Manolakis et al. 2013 [46] IBD: 350 61/700 33/548 1,490 0,960 to 2,31
HC: 274
Our study 2014 IBD:117 15/234 10/224 1,466 0,644 to 3,33
HC:112
Total (fixed effects) 891/12230 457/7244 1,154 1,021 to 1,30 0.015
Total (random effects) 891/12230 457/7244 1,306 1,006 to 1,69
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CD patients and HC and only one individual carried
the 399Ile variant at both alleles in UC. Co-segregation
of TLR4 polymorphic alleles was observed in only 33%
of controls (3 out of 9), 33% in UC (2 out of 6) and
60% in CD (6 out of 10).
Meta-analysis of our dataset with the published stud-
ies showed a significant association between TLR4
Asp299Gly variant allele and CD risk in a total of 5338
cases and 5076 controls (Pooled ORs = 1.35, 95% CI:
1.12-1.38; P = 0.0001) (Figure 1). In the other hand, no
association with UC was found when evaluating dis-
ease risk in 2592 patients and 3622 controls (Table 2),OR = 1.27, 95% CI = 0.95-1.69; P = 0.20 (Figure 2). Het-
erogeneity in odds ratios between studies was evi-
denced for CD (Q = 54.5, 23 df, P= 0.0002, I2 = 57.6%)
and UC (Q= 43.4%, 14 df, P= 0.0001,I2 = 67.8).
Combining Asp299Gly results for CD and UC (6115
cases and 3622 controls), an overall significant increased
risk for IBD was observed, OR = 1.15, 95% CI = 1.03-
1.30; P = 0.015 (Figure 3). However, a significant hetero-
geneity in allelic frequencies distribution is reported
(Cohran? s Q = 52.9, I2 = 73.6%).
Based on the studies published so far combined to our
results, we observed a significant association between the
T allele of the TLR4Thr399Ile Polymorphism and both CD
Table 6 Pooled analysis of studies exploring the role of TLR4 Thr399Ile in IBD
Study Sample size Cases (Events/Total) Controls (Events/Total) Odds 95% CI P value
Torok et al. 2004 [33] IBD: 200 38/400 12/290 2.432 1.24 to 4.74
HC: 145
Gazouli et al. 2005 [36] IBD: 205 4/410 2/200 0.975 0.17 to 5.37
HC: 100
Oostenbrug et al. 2005 [37] IBD: 721 93/1442 29/598 1.353 0.88 to 2.07
HC: 299
Zouiten-Mekki et al. 2009 [40] IBD: 120 15/240 8/160 1.267 0.52 to 3.06
HC: 80
Browning et al. 2007 [42] IBD: 794 106/1588 46/832 1.222 0.85 to 1.74
HC: 416
De Ridder et al. 2007 [23] IBD: 707 106/1414 22/488 1.717 1.07 to 2.75
HC: 244
Rigoli et al. 2008 [45] IBD: 178 12/356 6/206 1.163 0.43 to 3.14
HC: 103
Manolakis et al. 2013 [46] IBD: 350 61/700 33/548 1.490 0.96 to 2.31
HC: 274
Our study 2014 IBD: 117 10/234 3/224 3.289 0.89 to 12.11
HC: 112
Total (fixed effects) 445/6784 161/3546 1.479 1.22 to 1.82 0.0001
Total (random effects) 445/6784 161/3546 1.465 1.21 to 1.80
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variant increased the overall IBD susceptibility when
combining CD and UC results (OR = 1.46, 95%CI: 1.21-
1.76; P < 0.0001) for a total of 3392 cases and 1773 con-
trols (Figure 6).
In the present meta-analysis, we did not observed
heterogeneity between studies for TLR4Thr399Ile Poly-
morphism distribution in CD (Q = 9.05, DF = 11, I2 =
−21.54%; P = 0.62), UC (Q = 5.18, Df = 8, I2 = −54.4%; P =
0.73) and IBD (Cohran? sQ = 7.84, DF = 10, I2 = −27.5%;
P = 0.64).
Genotype-phenotype correlation was investigated; demo-
graphic and clinical characteristics of CD and UC patients
according to TLR4 polymorphisms are shown in (Tables 9
and 10). A significant association was found between theTable 7 Allele and genotype frequencies of the studied polym
ulcerative colitis and controls
Group TLR4 Asp299Gly
A G AA AG
CD (%) N = 83 157 (94.6) 9 (5.4) 74 (89.2) 9 (10.8)
UC (%) N = 34 62 (91.2) 6 (8.8) 28 (82.4) 6 (17.6)
Controls (%) N = 112 214 (95.5) 10 (4.5) 103 (92.0) 8 (7.1)need for surgery and possession of one or more Asp299gly
variant alleles in UC patients (P = 0.004). The presence
of TLR4 variant alleles was not associated with smok-
ing habits, age of diagnosis, disease location and be-
havior, family history and presence of extra-intestinal
manifestations. Separate analyses in men and women
did not reveal sex related associations. None of our UC
patients had an appendectomy. The correlation study
between Th399ILeu polymorphism and CD or UC
didn ? t allow to associate TLR4 genotype with a particu-
lar phenotype.
Discussion
Given the evidence that an altered innate immune re-
sponse and chronic inflammation are implicated in IBDorphisms in the group of patients with Crohn? s disease,
TLR4 Thr399Ile
GG C T CC CT TT
- 159 (95.8) 7 (4.2) 76 (91.6) 7 (8.4) -
- 65 (95.6) 3 (4.4) 32 (94.1) 1 (2.9) 1 (2.9)
1 (0.9) 221 (98.7) 3 (1.3) 109 (97.3) 3 (2.7) -
Table 8 Odds ratios and P values for association of TLR4
variants with IBD status
SNP Trait Genotype/Allele OR CI P Value
Asp299Gly CD AG 1.57 (0.58-4.25) 0.38
G 1.23 (0.49-3.09) 0.66
UC AG 2.76 (0.88-8.61) 0.08
G 2.07 (0.72-5.92) 0.17
Thr399Ile CD CT 3.35 (0.84-13.35) 0.09
T 3.24 (0.83-12.74) 0.09
UC CT 1.14 (0.11-11.29) 0.91
TT 10.11 (0.40-254.1) 0.16
T 3.4 (0.67-17.25) 0.14
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ceptors was clearly suggested as a trigger of CD and UC.
Several efforts were undertaken to demonstrate associa-
tions of the human TLR4 gene (Gene map locus 9q32-
q33) with IBD and its clinical manifestation. Attention
was focused on co-segregating SNPs located in exon 3
of TLR4 causing amino acid exchanges at positions 299
(Asp299Gly) and 399 (Thr399Ile) which are located in
the extracellular domain of the receptor [17,48]. Associ-
ation of TLR4 Asp299Gly with CD was first reported by
Braat et al. [30] subsequent studies have had divergent
results and showed strong evidence of ethnic differences.
In view of the discrepant data regarding the associationFigure 1 Forest plots for the association of TLR4 A299G and risk of Cof the TLR4 gene with IBD and its clinical complica-
tions, we investigated for the first time the potential
influence of TLR4 SNPs in the susceptibility to IBD in a
cohort of Moroccan patients. However, the statistical
power was very low and could be considered a limitation
in this study. Our study showed that the GG genotype
was not found in both CD and UC patients. No signifi-
cant differences were observed in allele frequencies of
the TLR4Asp299Gly among patients and controls. In
addition, although slightly increased frequencies of the
mutant alleles were encountered, we were not able to
identify a significant difference in allele distributions of
the TLR4Thr399Ile in our case ? control study. In line
with our results, a Tunisian study that genotyped 90
patients with CD and 80 healthy individuals for the
Asp299Gly and Thr399Ile polymorphisms, reported
the absence of association between CD and TLR4
gene in a north African population [40]. Although the
Tunisian CD population showed a similar overall pat-
tern of allelic frequencies, it is of some note that the
genotype-phenotype correlation revealed divergent re-
sults. While the Thr399Ile variant allele was associated
with early disease onset in Tunisian patients, no cor-
relation with a particular phenotype was observed for
this polymorphism in the Moroccan patients. Our
study showed that the presence of Asp299Gly variant
allele was associated with the need for surgery in UC
patients (P = 0.004). Furthermore, the occurrence of
one Asp299gly risk allele in CD patients was suggestiveD.
Figure 2 Forest plots for the association of TLR4 A299G and risk of UC.
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http://www.biomedcentral.com/1471-230X/14/206of a trend of association with smoking habits (P = 0.04)
that was no more observed after correction for mul-
tiple testing.
Being in linkage disequilibrium, TLR4 mutant alleles are
known to be inherited in the form of Asp299Gly/Thr399Ile
haplotype [48]. In a German cohort, the co-segregationFigure 3 Forest plots for the association of TLR4 A299G and risk of IBD.between mutant alleles represented 100% in controls,
whereas it was not complete in CD and UC patients: 94%
and 86% respectively [33]. These observations contrast our
findings where simultaneous presence of the mutated al-
leles was only observed in 33% of controls, 33% of UC and
60% of CD patients.
Figure 4 Forest plots for the association of TLR4 T399I and risk of CD.
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http://www.biomedcentral.com/1471-230X/14/206Results on the relationship of Asp299Gly SNP alone
or in combination with Thr399Ile with IBD are incon-
sistent between studies. No difference in TLR4 allele fre-
quency between IBD patients and controls was observed
in Hungarian [35], Saudi Arabian [47], Southern ItalianFigure 5 Forest plots for the association of TLR4 T399I and risk of UC[45], New Zealandian [41] and EC-IBD [43] study groups
populations. Genetic heterogeneity within Europe was
evidenced by Arnott et al. when reporting lack of associ-
ation of TLR4 and CD14 variants in Scottish and Irish
CD patients [31]. Moreover, Baumgart DC et al. reported.
Figure 6 Forest plots for the association of TLR4 T399I and risk of IBD.
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promoter but not with the TLR4 (p.D299G) variant in
Germans and Hungarians [21]. Interestingly, the hetero-
zygous and homozygous pattern for the mutated allele
was not detected in any of the individuals from the
Japanese [49], Korean [24], Chinese Han population [25]
and Zhuang population from the Guangxi Zhuang
Autonomous Region of China [26]. TLR4 was linked to
an increased IBD (CD or UC) risk in many other diverse
investigations. Significant associations were found in pa-
tients drawn from Belgian [32], German [22,33], Greek
[36,46] and Dutch [34] populations. In addition, several
meta-analyses provided evidence that the Asp299Gly
SNP is associated with CD and IBD in Caucasians
[27,42,50]. The results of our meta-analysis indicate a
significant association between TLR4 Thr399Ile and
CD and UC risk in different populations. Noteworthy, a
lack of heterogeneity between studies was observed re-
garding distribution of this polymorphism. The results
support that this variant is a potential risk factor for
IBD.
A correlation between Asp299Gly variant and an in-
creased disease risk is also reported for CD and IBD
but not regarding UC, which is in line with de Jager
et al. findings [28]. This indicates that the risk allele is
either not associated with disease susceptibility or that
the small number of UC cohorts did not provide suffi-
cient power to detect an association. A correlation between
TLR4 polymorphisms and UC has been rarely discussed,more association studies are needed to validate the
conclusion.
To date it is well known that the frequency of the in-
vestigated TLR4 gene SNPs varies between populations
[27,31]. Overall, there was inescapable evidence for
considerable genetic heterogeneity. This observation
has been explained by geographic and ethnicity-related
gene effect on disease susceptibility [51]. Our results
showed that the distribution of the risk alleles varies
between both TLR4 polymorphisms. Therefore, we offer
additional evidence for differences in the contribution
of individual genetic determinants between populations.
Browning et al., argued that negative studies with re-
sults that do not achieve statistical significance can still
contribute evidence for association, having important
implications for the first generation of whole genome
association studies [42].
In view of the role of potential confounders related to
the present study and to discrepant results between
populations, it is likely that the contribution of different
sample size, selection bias, phenotypic heterogeneity and
population stratification in case control studies can ? t be
ruled out. These data demonstrate further the real diffi-
culties in candidate gene analysis in complex diseases.
Moreover, given that IBD is a polygenic disease it is
provided that association studies will reveal various
sets of susceptible genes. Therefore, further large-scale
studies are required to obtain a clear insight into the
impact of the pattern recognition receptors in the
Table 9 Genotype-phenotype correlations in patients with Crohn ? s disease
Parameter N Asp299gly (%) P value Chi-square test Thr399Ile (%) P value Chi-square test
AA AG GG CC CT TT
Age of onset 83 0.48 1.45 0.59 1.05
<17 years 10 10 (100.0) - 10 (100.0) -
17-40 63 55 (87.3.) 8 (12.7) 57 (90.5) 6 (9.5)
>40 years 10 9 (90.0) 1 (10.0) 9 (90.0) 1 (10.0)
Sex 83 0.35 0.87 0.17 1.92
Woman 25 24 (96.0) 1 (4.0) 25 (100.0) -
Man 58 50 (86.2) 8 (13.8) 51 (87.9) 7 (12.1)
Type 83 0.54 2.14 0.36 3.23
Fistulizing 35 31 (88.6) 4 (11.4) 33 (94.3) 2 (5.7)
Non fistulizing non stenosing 24 20 (83.3) 4 (16.7) 20 (83.3) (16.7)
Stenosing 17 16 (94.1) 1 (5.9) 16 (94.1) 1 (5.9)
Fistulizing stenosing 7 7 (100.0) - 7 (100.0) -
Localization 83 0.80 1.67 0.94 0.82
L1 30 26 (86.7) 4 (13.3) 27 (90.0) 3 (10.0)
L2 20 17 (85.0) 3 (5.0) 18 (90.0) 2 (10.0)
L3 26 24 (92.3) 2 () 24 (92.3) 2 (7.7)
L4 3 3 (100.0) - 3 (100.0) -
L4 + L2 4 4 (100.0) - 4 (100.0) -
Smoking 83 0.04 4.44 0.17 1.92
Presence 33 26 (78.8) 7 (21.2) 28 (84.8) 5 (15.2)
Absence 50 48 (96.0) 2 (4.0) 48 (96) 2 (4.0)
SFC 83 0.91 0.01 0.76 0.09
Presence 4 4 (100.0) - 4 (100.0) -
Absence 79 70 (88.6) 9 (11.4) 72 (91.1) 7 (8.9)
Appendectomy 83 0.84 0.04 0.58 0.30
Presence 12 11 (91.7) 1 (8.3) 10 (83.3) 2 (16.7)
Absence 71 63 (88.7) 8 (11.3) 66 (93.0) 5 (7.0)
EIM 83 0.97 0.001 0.97 0.001
Presence 42 38 (90.5) 4 (9.5) 39 (92.9) 3 (7.1)
Absence 41 36 (87.8) 5 (12.2) 37 (95.1) 4 (4.9)
Surgery 83 0.50 0.45 0.45 0.57
Presence 41 38 (92.7) 3 (7.3) 39 (95.1) 2 (4.9)
Absence 42 36 (85.7) 6 (14.3) 37 (88.1) 5 (11.9)
SFC: similar familial cases; EIM: extra intestinal manifestations; N: total number; AA: wild type TLR4 Asp299gly, AG: TLR4 Asp299gly heterozygous variant, GG: TLR4
Asp299gly homozygous variant; CC: wild type TLR4 Thr399Ile, CT: TLR4 Thr399Ile heterozygous variant, TT: TLR4 Thr399Ile homozygous variant.
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and to explore the contribution of other genes involved in
various processes.Conclusions
In the present study, we have demonstrated that the
common mutations in the TLR4 gene are not associated
with IBD in a sample of Moroccan patients. However,our dataset contributed to the significant association
observed in TLR4 meta-analysis.
It is likely that the distribution of TLR4 gene polymor-
phisms have ethnic differences. Our data suggests that
other genetic and environmental factors may play a role
in IBD susceptibility and behavior in this population.
However, because of the relatively small sample size,
additional well-powered studies are needed to confirm
our findings.
Table 10 Genotype-phenotype correlations in patients with ulcerative colitis
Parameter N Asp299gly (%) P
value
Chi-square test Thr399Ile (%) P value Chi-square test
AA AG GG CC CT TT
Age of onset 34 0.35 0.89 0.34 2.13
<17 years - - - - -
17-40 20 18 (90.0) 2 (10.0) - 19 (95.0) 1 (5.0) -
>40 years 14 10 (71.4) 4 (28.6) - 13 (92.9) - 1 (7.1)
Sex 34 0.89 0.018 0.36 2.06
Woman 15 13 (86.7) 2 (13.3) - 14 (93.3) 1 (6.7) -
Man 19 15 (78.9) 4 (21.1) - 18 (94.7) - 1 (5.3)
Extent of the disease 34 0.31 3.55 0.16 9.34
E1 4 2 (50.0) 2 (50.0) - 3 (75.0) - 1 (25.0)
E2 15 13 (86.7) 2 (13.3) - 15 (100.0) - -
E3 2 2 (100.0) - - 2 (100.0) - -
E4 13 11 (84.6) 2 (15.4) - 12 (92.3) 1 (7.7) -
SFC 34 0.39 0.74 0.97 0.06
Presence 1 1 (100.0) - - 1 (100.0) -
Absence 33 27 (81.8) 6 (18.2) - 31 (93.9) 1 (3.0) 1 (3.0)
Smoking 34 0.93 0.008 0.20 3.17
Presence 9 7 (77.8) 2 (22.2) - 8 (88.9) - 1 (11.1)
Absence 25 21 (84.) 4 (16.0) - 24 (96.0) 1 (4.0) -
EIM 34 0.89 0.018 0.35 2.05
Presence 19 15 (78.9) 4 (21.1) - 18 (94.7) - 1 (5.3)
Absence 15 13 (86.7) 2 (13.3) - 14 (93.3) 1 (6.7) -
Surgery 34 0.004 8.3 0.08 4.97
Presence 6 2 (33.3) 4 (66.7) - 5 (83.3) 1 (16.7) -
Absence 28 26 (92.9) 2 (7.1) - 27 (96.4) - 1 (3.6)
SFC: similar familial cases; EIM: extra intestinal manifestations; N: total number; AA: wild type TLR4 Asp299gly, AG: TLR4 Asp299gly heterozygous variant, GG: TLR4
Asp299gly homozygous variant; CC: wild type TLR4 Thr399Ile, CT: TLR4 Thr399Ile heterozygous variant, TT: TLR4 Thr399Ile homozygous variant.
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